Get the Daily Brief
Latest Biotech News
Qiagen to buy Parse Biosciences — single‑cell consolidation deepens
Qiagen announced an agreement to acquire Seattle‑based Parse Biosciences for up to $280 million, folding a high‑throughput single‑cell library prep company into a larger public instrument and...
Novo ups Metsera bid — FTC flags deal structure for review
Novo Nordisk raised its offer for obesity biotech Metsera in a contested sale that also drew a formal staff letter from the Federal Trade Commission raising concerns about the transaction’s...
Evommune prices $150M IPO — inflammation biotech lists amid shutdown
Evommune, a clinical‑stage inflammation biotech with late‑stage data in chronic inducible urticaria, priced an initial public offering for approximately $150 million and began trading on the NYSE....
CRISPR trial halted after patient death: Intellia updates
Intellia Therapeutics reported the death of a patient who had been hospitalized with liver injury after receiving nex‑z, its LNP‑delivered in vivo CRISPR base‑editing therapy for transthyretin...
White House cuts obesity drug prices; FDA grants priority vouchers
The Trump administration struck agreements with Novo Nordisk and Eli Lilly to lower prices and expand access to leading obesity drugs and announced plans for a government drug portal. In parallel,...
Novo-Pfizer Metsera fight draws antitrust scrutiny
Novo Nordisk continued to raise its bid for obesity biotech Metsera amid a heated auction with Pfizer, and the Federal Trade Commission flagged concerns about the structure of Novo’s proposal. FTC...
Lilly’s amylin drug drives 20% weight loss — amylin debate heats up
Eli Lilly disclosed Phase 2 data linking its amylin receptor agonist eloralintide to up to 20.1% mean weight loss at 48 weeks and announced plans to start Phase 3. The data showed dose‑dependent...
Arima Genomics pushes Hi‑C assay to challenge FISH in lymphoma
Arima Genomics touted results from its Aventa Hi‑C lymphoma assay that detected clinically significant gene fusions and structural rearrangements in FFPE lymphoma samples where FISH was...
Hepta emerges with cfDNA epigenetics to detect MASH — raises seed
Hepta, founded by former Illumina and Grail personnel, surfaced from stealth with transformer‑based AI that reads the cell‑free DNA epigenome to detect organ‑specific chronic disease signals and...
Ginkgo wins BARDA award to scale monoclonal antibody manufacturing
Ginkgo Bioworks secured a BioMaP‑Consortium award from BARDA valued up to $22.2M to develop cost‑reducing, rapid domestic manufacturing technologies for monoclonal antibodies against filoviruses...
BIOVECTRA and Revolution link mRNA design to GMP manufacturing
BIOVECTRA and Revolution Biomanufacturing announced a partnership to integrate Revolution’s sequence‑optimization platforms for UTRs and codon usage with BIOVECTRA’s end‑to‑end GMP capabilities...
MIT lipid nanoparticle breakthrough could slash mRNA dose 100x
Researchers at MIT reported a novel lipid nanoparticle that dramatically enhanced mRNA vaccine potency in preclinical work, claiming the formulation could reduce required dose by up to 100‑fold....
Zuckerberg’s Biohub expands with EvolutionaryScale AI team
Mark Zuckerberg and Priscilla Chan’s Chan Zuckerberg Initiative reorganized its science portfolio and folded EvolutionaryScale into a unified Biohub effort, hiring EvolutionaryScale’s team and...
Intellia CRISPR trial paused: patient dies after liver injury
A patient in Intellia Therapeutics’ in vivo CRISPR trial for transthyretin amyloidosis (nex‑z) has died, compounding safety concerns that halted dosing in two Phase 3 studies. Intellia reported...
MIT LNPs promise 100x potency — RNA elements extend mRNA durability
Two independent advances target core limitations of mRNA therapeutics: delivery potency and molecular durability. MIT researchers engineered a novel lipid nanoparticle that greatly enhances...
Lilly’s amylin delivers up to 20% weight loss — phase 3 imminent
Eli Lilly reported robust Phase 2 results for its amylin receptor agonist eloralintide, with some cohorts reaching approximately 20% mean weight loss at 48 weeks and a tolerability profile Lilly...
FDA grants second wave of 'national priority' vouchers — obesity drugs among winners
The FDA released a second tranche of Commissioner’s National Priority Vouchers (CNPVs), adding six drugs to the program designed to speed review and support domestic priorities. The second round...
Metsera bidding war escalates: Novo ups bid as court refuses Pfizer block
The auction for Metsera intensified as Novo Nordisk raised its takeover bid to counter Pfizer, while a Delaware court denied Pfizer’s emergency request to block Novo’s offer. Regulators and...
Site‑specific recombinases debut — Azalea exits stealth to target in vivo gene engineering
Two developments advance in vivo gene engineering tools and companies. A Nature Biotechnology paper describes engineered recombinases capable of precise, site‑specific DNA insertion in human cells...
AI designs antibodies with atomic precision — Baker weighs in
Researchers applied RFdiffusion and a hypermutation pipeline to design de novo antibodies that bind user‑specified epitopes with atomic precision, validating designs by cryo‑EM across multiple...